Killing two birds with one stone : response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 32(2018), 2 vom: 26. Feb., Seite e72-e74 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arenbergerova, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 26.08.2019 Date Revised 26.08.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.14537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275066371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275066371 | ||
| 003 | DE-627 | ||
| 005 | 20231225004835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.14537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0916.xml |
| 035 | |a (DE-627)NLM275066371 | ||
| 035 | |a (NLM)28833722 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arenbergerova, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Killing two birds with one stone |b response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.08.2019 | ||
| 500 | |a Date Revised 26.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Fialova, A |e verfasserin |4 aut | |
| 700 | 1 | |a Arenberger, P |e verfasserin |4 aut | |
| 700 | 1 | |a Gkalpakiotis, S |e verfasserin |4 aut | |
| 700 | 1 | |a Jirasek, T |e verfasserin |4 aut | |
| 700 | 1 | |a Srp, A |e verfasserin |4 aut | |
| 700 | 1 | |a Novotna, A |e verfasserin |4 aut | |
| 700 | 1 | |a Frankova, H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 32(2018), 2 vom: 26. Feb., Seite e72-e74 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:2 |g day:26 |g month:02 |g pages:e72-e74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.14537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2018 |e 2 |b 26 |c 02 |h e72-e74 | ||